Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerab...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Pharmacol
Glavni autori: Marzin, Kristell, Kretschmar, Gunther, Luedtke, Doreen, Kraemer, Sandrine, Kuelzer, Raimund, Schlenker‐Herceg, Rozsa, Schmid, Ulrike, Schnell, David, Dallinger, Claudia
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Special Populations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836871/
https://ncbi.nlm.nih.gov/pubmed/29106740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1025
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items